On July 6, Thermo Fisher Scientific declined 3.05% in regular trading, trading at approximately $509.69/share, with turnover of $164 million. The decline was driven by a combination of an analyst target price reduction and broad weakness across the life sciences tools sector.

Evercore ISI lowered its price target on Thermo Fisher Scientific to $570 from $575 while maintaining its Outperform rating. The stock currently carries a consensus mean price target of $595 with an overweight average rating. At the sector level, life sciences tools and services stocks faced broad selling pressure, with peer Danaher declining 3.59% during the same session, highlighting significant sector-wide linkage effects.

The company is scheduled to report next quarterly earnings on July 23 before market open, with analysts expecting adjusted EPS of $5.71. In its most recent quarter, Thermo Fisher beat consensus estimates with adjusted EPS of $5.44 versus the $5.24 estimate, while revenue of $11.005 billion also exceeded the $10.853 billion forecast.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)